Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

NCT ID: NCT00258323

Last Updated: 2015-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2010-02-28

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Cisplatin and fluorouracil may also make tumor cells more sensitive to radiation therapy. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radiation therapy together with combination therapy and gefitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving radiation therapy together with combination chemotherapy and gefitinib before and after surgery works in treating patients with advanced esophageal or gastroesophageal junction cancer.

Detailed Description

OBJECTIVES:

Primary

• Determine the activity of gefitinib, in terms of median survival and distant metastatic disease control, in patients treated with neoadjuvant and adjuvant cisplatin, fluorouracil, and radiotherapy who are undergoing surgery for esophageal and gastroesophageal junction cancer.

Secondary

• Determine the pathologic complete and partial response rate in patients treated with this regimen.
• Determine the toxicity of this regimen in these patients and in patients who are disease free and receiving long-term maintenance gefitinib.

OUTLINE:

• Preoperative regimen: Patients undergo radiotherapy twice a day during days 1-12 (for a total of 10 treatment days). Patients receive fluorouracil IV continuously and cisplatin IV continuously on days 1-4. Patients also receive oral gefitinib once daily on days 1-28. At 6 weeks, patients with locoregionally confined disease undergo surgical resection and then proceed to the postoperative regimen. Patients with a medical contraindication to surgery proceed directly to the postoperative regimen.
• Postoperative regimen: Beginning 4-10 weeks after surgery or 6 weeks after completing the first course of therapy, patients undergo radiotherapy and receive fluorouracil and cisplatin as in the preoperative regimen.
• Maintenance regimen: Patients receive oral gefitinib beginning on day 1 of the postoperative regimen and continuing for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.

Conditions

Esophageal Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

cisplatin

20mg/m2d/IV continuous infusion x days

Intervention Type: DRUG

fluorouracil

1000mg/m2/d IV continuous infusion x 4 days

Intervention Type: DRUG

Iressa

250mg po qd days 1-28 then x 2 years

Intervention Type: DRUG

conventional surgery

conventional surgery

Intervention Type: PROCEDURE

radiation therapy

150 cGy bid

Intervention Type: RADIATION

Other Intervention Names

CDDP; 5 FU; ZD 1839

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed squamous cell carcinoma, adenocarcinoma, or large cell undifferentiated cancer of the esophagus or gastroesophageal junction

• T3, N1, or M1a disease only
• The following types are not allowed:

• Small cell undifferentiated carcinomas, lymphomas, or sarcomas
• Small cell or mixed small cell/non-small cell histology
• No evidence of distant hematogenous tumor metastases (M1b)
• No malignant pleural effusions

PATIENT CHARACTERISTICS:

Performance status

• ECOG 0-1

Life expectancy

• Not specified

Hematopoietic

• WBC > 3,500/mm^3
• Platelet count > 100,000/mm^3

Hepatic

• Alkaline phosphatase < 2 times normal
• AST < 2 times normal
• No unstable or uncompensated hepatic disease

Renal

• Creatinine ≤ 2.0 mg/dL
• Calcium normal
• No unstable or uncompensated renal disease

Cardiovascular

• No unstable or uncontrolled angina
• No unstable or uncompensated cardiac disease

Pulmonary

• See Disease Characteristics
• No limitations to pulmonary function that would preclude study participation
• No evidence of clinically active interstitial lung disease (asymptomatic patients with chronic stable radiographic changes are allowed)
• No unstable or uncompensated respiratory disease

Other

• Not pregnant or nursing
• Fertile patients must use effective contraception
• No evidence of severe or uncontrolled systemic disease
• No other uncontrolled malignancy
• No active infection
• No known severe hypersensitivity to gefitinib or any of its excipients

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior immunotherapy for this cancer

Chemotherapy

• No prior chemotherapy for this cancer

Radiotherapy

• No prior radiotherapy for this cancer

Surgery

• Recovered from any prior oncologic or other major surgery
• No prior surgical resection for this cancer
• No concurrent ophthalmic surgery

Other

• No prior photodynamic therapy for this cancer (prior laser treatments are acceptable)
• More than 30 days since prior unapproved or investigational drug
• No concurrent phenytoin, carbamazepine, barbiturates, rifampin, phenobarbital, or Hypericum perforatum (St. John's wort)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Case Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David J. Adelstein, MD

Role: STUDY_CHAIR

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Locations

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Countries

United States

Related Links

http://clinicaltrials.gov/ct2/results?term=ccf5848

Clinical trial summary from the National Cancer Institute's PDQ® database

Other Identifiers

P30CA043703

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CCF-5848

Identifier Type: OTHER

Identifier Source: secondary_id

ZENECA-1839/US/0233

Identifier Type: -

Identifier Source: secondary_id

CCF5848

Identifier Type: -

Identifier Source: org_study_id